N-acetylcysteine, a mucus-thinning drug also sold as a dietary supplement, supplies the building block for the body's main antioxidant. Its best-supported benefit is a modest drop in lung flare-ups in chronic bronchitis or long-term lung disease. Risks at usual doses appear mild, mainly digestive discomfort, but it can blunt muscle recovery after hard training. For healthy adults, the case rests more on plausible biology than on proven long-term outcomes. (Full Review)

Protocol

Standard regimen

600 mg twice daily

1,200 mg/day, the dose in the COPD, influenza and hemodialysis trials; 600 mg once daily failed to reduce flare-ups in one trial, though the Cochrane review found no clear dose effect

Single vs split dose

Split, morning and evening

Matches the half-life and the twice-daily regimens of the main trials; no trial has compared timing

Baseline biomarker

Blood glutathione

Low blood glutathione predicted performance benefit in one trial; testing may help decide whether supplementation is worthwhile

Time to effect

COPD flare-up reduction

Months

Trials longer than five months confirmed benefit

Hair-pulling

9 weeks

Improved after nine weeks in one trial

Exercise performance when glutathione is low

30 days

Restored glutathione and improved performance in one trial

Benefits

High: Fewer flare-ups of chronic bronchitis and COPD; less hearing loss with aminoglycoside antibiotics; lower mortality in hospitalized COVID-19

Medium: Survival after acetaminophen poisoning; less atrial fibrillation after heart surgery; fewer depressive symptoms as add-on therapy; fewer compulsive behaviors and less craving; fewer symptomatic influenza-like episodes in older adults; fewer cardiovascular events in people on hemodialysis; better exercise performance when glutathione is low; pregnancy and ovulation in polycystic ovary syndrome; better semen quality in men with idiopathic infertility; lower rheumatoid arthritis disease activity as add-on therapy

Low: Physical function and glutathione in older adults, with glycine; transplant-free survival in non-acetaminophen acute liver failure; survival in severe alcohol-associated hepatitis, with corticosteroids; organ protection during hospital procedures; slower lung-function decline in idiopathic pulmonary fibrosis; fewer psychotic symptoms in schizophrenia as add-on therapy

Speculative: Longer lifespan; lower markers of systemic inflammation

Contraindications

People with a previous hypersensitivity reaction to acetylcysteine

People taking nitrates for angina, unless supervised

People with active cancer or under cancer treatment

Key Interactions

Activated charcoal (over-the-counter gas and poisoning remedies): reduced NAC levels and effect

Theoretical (inferred from mechanism)

Antiplatelet drugs and anticoagulants (aspirin, warfarin): possible additive bleeding tendency

Phosphodiesterase-5 inhibitors (sildenafil) and blood-pressure drugs (amlodipine): possible dizziness or low blood pressure

Chemotherapy and radiotherapy relying on oxidative damage (cisplatin): possible reduced anticancer effect

Cough suppressants (dextromethorphan): possible pooling of loosened mucus in people with chest infections

Nitric-oxide-boosting supplements (L-arginine, beetroot nitrate): possible low blood pressure or headache

High-dose antioxidant supplements (vitamin C, vitamin E): possible blunted training adaptation

Risk & Side Effects

Medium: Impaired muscle recovery after damaging exercise; gastrointestinal and minor adverse effects

Low: Hypersensitivity reactions with intravenous use; fluid overload with intravenous dosing; brain swelling and red-cell breakdown after intravenous overdose; faster tumor progression

Speculative: High blood pressure in the lung arteries

Monitoring

Marker	Target	Why
Blood glutathione (reduced-to-oxidized GSH:GSSG ratio)	No established target; track change from own baseline	Identifies deficiency
Seated and standing blood pressure	No established target; track seated value and standing drop from own baseline	Safety check with nitrates or vasodilators
F2-isoprostanes (urine or plasma)	No established target; track change from own baseline	Oxidative damage marker
Lung function (people with COPD)	Not specified in the ER	Outcome baseline
Yearly flare-up count (people with COPD)	Not specified in the ER	Outcome baseline

Cadence: Baseline before starting; repeat glutathione test at 1–3 months, then every 6–12 months while taking NAC; blood pressure rechecked within 1–2 weeks of adding NAC to vasodilating drugs; COPD flare-up frequency reviewed after 6–12 months

Qualitative Assessment

Fewer or milder chest infections and flare-ups, with easier mucus clearance
Fewer or shorter winter respiratory illnesses
Mood stability and reduced cravings or compulsive urges, where these were goals
Training recovery and strength progression unchanged or improved
Gastrointestinal comfort on the chosen dose

N-Acetylcysteine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment